Drugs / LCAR-B4822M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03674463 | Jul 2018 → Dec 2020 | refractory plasma cell neoplasm | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-B4822M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03674463 ↗ |
| Modality | Cell therapy | “LCAR-B4822M CAR-T cells” NCT03674463 ↗ |
| Route | Intravenous | “receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection” NCT03674463 ↗ |